Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Bristol Settles DoJ "Channel Stuffing" Investigation For $300 Mil.

This article was originally published in The Pink Sheet Daily

  • News
  • Lee Kalowski

Executive Summary

The company will take a $249 mil. charge in the second quarter, in addition to a first quarter charge of $51 mil. The monies will be added to a shareholder fund created under a separate, earlier settlement with SEC. CEO Dolan loses his chairman's title under the pact, and Bristol agrees to cooperate with investigations of former executives.

You may also be interested in...



Bristol Reaches Tentative Settlement With U.S. Attorney

The firm could pay $499 million in civil penalties to settle pricing, sales and marketing charges.

Bristol Reaches Tentative Settlement With U.S. Attorney

The firm could pay $499 million in civil penalties to settle pricing, sales and marketing charges.

Bristol’s Termination Of Dolan Follows Federal Monitor’s Recommendation

However, the company’s monitor and the U.S. Attorney for New Jersey conclude that Bristol has not violated a deferred prosecution agreement.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS062384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By